← FDA DRUG APPROVALS

FDA NDA · NDA208746

PEMETREXED DITROMETHAMINE

Sponsor: HOSPIRA

APPLICATION
NDA208746
TYPE
NDA
ORIGINAL APPROVAL
2022-06-10
LATEST ACTION
2022-06-10
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Discontinued

Products

PEMETREXED DITROMETHAMINE · ReferenceDiscontinued
PEMETREXED DITROMETHAMINE EQ 1GM BASE/VIAL · POWDER · INTRAVENOUS
PEMETREXED DITROMETHAMINE · ReferenceDiscontinued
PEMETREXED DITROMETHAMINE EQ 100MG BASE/VIAL · POWDER · INTRAVENOUS
PEMETREXED DITROMETHAMINE · ReferenceDiscontinued
PEMETREXED DITROMETHAMINE EQ 500MG BASE/VIAL · POWDER · INTRAVENOUS

Approval history

2022-06-10Type 3 - New Dosage Form · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →